• 1
    Roehrborn CG, Bartsch G, Kirby R et al. Guidelines for the diagnosis and treatment of benign prostatic hyperplasia: a comparative, international overview. Urology 2001; 58: 64250
  • 2
    Djavan B, Marberger M. A meta-analysis on the efficacy and tolerability of α1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999; 36: 113
  • 3
    Michel MC, Flannery MT, Narayan P. Worldwide experience with alfuzosin and tamsulosin. Urology 2001; 58: 50816
  • 4
    Jardin A, Bensadoun H, Delauche-Cavallier MC et al. Alfuzosin for treatment of benign prostatic hypertrophy. Lancet 1991; 337: 145761
  • 5
    Buzelin JM, Roth S, Geffriaud-Ricouard C et al. Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia. Eur Urol 1997; 31: 1908
  • 6
    Teillac P, Delauche-Cavallier MC, Attali P. Urinary flow rates in patients with benign prostatic hypertrophy following treatment with alfuzosin. Br J Urol 1992; 70: 5864
  • 7
    Lukacs B, Grange JC, Comet D et al. Three-year prospective study of the 3228 BPH patients treated with alfuzosin in general practice. Prostate Cancer Prostatic Dis 1998; 1: 27683
  • 8
    Buzelin JM, Delauche-Cavallier MC, Roth S et al. Clinical uroselectivity: evidence from patients treated with slow-release alfuzosin for symptomatic benign prostatic obstruction. Br J Urol 1997; 79: 898906
  • 9
    Debruyne FM, Jardin A, Colloi D et al. Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. Eur Urol 1998; 34: 16975
  • 10
    McKeage K, Plosker GL. Alfuzosin. A review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs 2002; 62: 63353
  • 11
    Roehrborn CG, for the ALFUS Study Group. Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial. Urology 2001; 58: 9539
  • 12
    Van Kerrebroeck P, Jardin A, Laval KU et al. Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. Eur Urol 2000; 37: 30613
  • 13
    Roehrborn CG, Osterling JE, Auerbach S et al. The Hytrin Community Assessment Trial study. A one-year study of terazosin versus placebo in the treatment of men with benign prostatic hyperplasia. Urology 1996; 47: 15968
  • 14
    Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology 1998; 51: 892900
  • 15
    Roehrborn CG, Siegel RL. Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. Urology 1996; 48: 40615
  • 16
    Lepor H, for the Tamsulosin Investigator Group. Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Urology 1998; 51: 9016
  • 17
    Hofner K, Jonas U. Alfuzosin: a clinically uroselective alpha1-blocker. World J Urol 2002; 19: 40512
  • 18
    Narayan P, Bruskewitz R. A comparison of two phase III multicenter, placebo-controlled studies of tamsulosin in BPH. Adv Ther 2000; 17: 287300
  • 19
    Moriyama N, Nasu K, Takeuchi T et al. Quantification and distribution of alpha 1-adrenoceptor subtype mRNAs in human vas deferens: comparison with those of epididymal and pelvic portions. Br J Pharmacol 1997; 122: 100914
  • 20
    Giuliano F, Allard J, McKenna et al. Tamsulosin has more deleterious effects than alfuzosin on parameters characterizing ejaculation in anaesthetized rats. Int J Impot Res 2002; 14 (Suppl 3): S12